Community Advisory Board

Readers Rep

Markets:

Overview

News

Currencies

International

Treasuries

Phio Pharmaceuticals Corp. - Common Stock (NQ:PHIO)

1.065 -0.015 (-1.39%)

Streaming Delayed Price Updated: 3:42 PM EDT, Jun 18, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Phio Pharmaceuticals Corp. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

April 09, 2025

Via Benzinga

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Study to Fourth Dose Escalation Cohort

April 09, 2025

Marlborough, Massachusetts--(Newsfile Corp. - April 9, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing...

Via Newsfile

Phio Pharmaceuticals Announces Podium Presentations on INTASYL siRNA Lead Product Candidates PH-762 and PH-894

April 03, 2025

To be presented at 11th Annual Immunotherapy of Cancer (ITOC) Conference in Munich, Germany Marlborough, Massachusetts--(Newsfile Corp. - April 3,...

Via Newsfile

Phio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business Update

March 31, 2025

Continues advancing clinical trial for INSTASYL siRNA lead product candidate PH-7623rd Cohort now fully enrolled in on-going clinical studyMarlborough, Massachusetts--(Newsfile...

Via Newsfile

What's Going On With Phio Pharmaceuticals Stock Today? ↗

January 14, 2025

Phio Pharmaceuticals stock drops 39.1% after announcing a $3.19 million direct offering and concurrent private placement.

Via Benzinga

American Academy of Dermatology Awards Podium Presentation to Phio Pharmaceutical's Clinical Research at 2025 Annual Meeting

March 10, 2025

Marlborough, Massachusetts--(Newsfile Corp. - March 10, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics...

Via Newsfile

Phio Pharmaceuticals Announces Completion of Enrollment in Third Safety Cohort in PH-762 Phase 1b Dose-Escalation Study

March 05, 2025

Marlborough, Massachusetts--(Newsfile Corp. - March 5, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics...

Via Newsfile

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

February 26, 2025

Marlborough, Massachusetts--(Newsfile Corp. - February 26, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) a clinical-stage biotechnology company developing therapeutics that...

Via Newsfile

Phio Pharmaceuticals Announces Appointment of David H. Deming to Board of Directors

February 20, 2025

Marlborough, Massachusetts--(Newsfile Corp. - February 20, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics...

Via Newsfile

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

February 03, 2025

Marlborough, Massachusetts--(Newsfile Corp. - February 3, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics...

Via Newsfile

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

January 22, 2025

Marlborough, Massachusetts--(Newsfile Corp. - January 22, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics...

Via Newsfile

Phio Pharmaceuticals Announces Closing of $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

January 21, 2025

Raised approximately $12.08 million in gross proceeds since beginning of December 2024 Proceeds intended to be directed for development costs...

Via Newsfile

Phio Pharmaceuticals Announces $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

January 16, 2025

Marlborough, Massachusetts--(Newsfile Corp. - January 16, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company that develops therapeutics...

Via Newsfile

Topics Regulatory Compliance

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

January 15, 2025

Via Benzinga

Phio Pharmaceuticals Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

January 15, 2025

Marlborough, Massachusetts--(Newsfile Corp. - January 15, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company that develops therapeutics...

Via Newsfile

Topics Regulatory Compliance

Dow Gains Over 200 Points; Signet Jewelers Shares Plunge ↗

January 14, 2025

Via Benzinga

Topics Stocks

We Asked Retail What's Next For Phio Pharma After Monday's Blistering Rally: Most See More Room To Run ↗

January 14, 2025

Around 34% foresee a pullback, while 13% are uncertain due to the stock's volatility.

Via Stocktwits

Crude Oil Down 1%; Firefly Neuroscience Shares Spike Higher ↗

January 14, 2025

Via Benzinga

Nasdaq Jumps 150 Points; US Producer Prices Increase 0.2% In December ↗

January 14, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

January 14, 2025

Via Benzinga

Phio Pharmaceuticals Announces $3.19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

January 14, 2025

Marlborough, Massachusetts--(Newsfile Corp. - January 14, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company that develops therapeutics...

Via Newsfile

Topics Regulatory Compliance

Why KB Home Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket ↗

January 14, 2025

Via Benzinga

Stocks to Watch in 2025: PHIO, LPTH, KAVL, Promising Innovations, Growth Opportunities, Etc. … more inside

January 13, 2025

Via AB Newswire

Topics Regulatory Compliance

Gold Down Over 1%; Salarius Pharmaceuticals Shares Surge ↗

January 13, 2025

Via Benzinga

Cancer-Focused Phio Pharmaceuticals Stock Gains 300% On Monday - Here's Why ↗

January 13, 2025

Phio Pharmaceuticals reports promising Phase 1b trial results for PH-762, showing complete tumor clearance in two patients with no significant adverse effects.

Via Benzinga

Phio Pharma Stock Quadruples On Positive Data From Cancer Treatment Trial: Retail’s Elated ↗

January 13, 2025

CEO Robert Bitterman highlighted the potential of Phio’s proprietary INTASYL RNAi technology, which targets proteins that hinder the body’s immune response to cancer.

Via Stocktwits

Crude Oil Surges 3%; Abercrombie & Fitch Shares Plunge ↗

January 13, 2025

Via Benzinga

US Stocks Mixed; Nasdaq Down Over 1% ↗

January 13, 2025

Via Benzinga

Phio Pharmaceuticals Announces Promising Results of Second Cohort from Its Ongoing Clinical Study of PH-762

January 13, 2025

Marlborough, Massachusetts--(Newsfile Corp. - January 13, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics...

Via Newsfile

Phio Pharmaceuticals Announces Publication in Clinical, Cosmetic and Investigational Dermatology

January 02, 2025

Marlborough, Massachusetts--(Newsfile Corp. - January 2, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics...

Via Newsfile

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

About Us

Phio Pharmaceuticals Corp. - Common Stock (NQ:PHIO)

All News about Phio Pharmaceuticals Corp. - Common Stock